Purchases and Sales Made in Q3 2023 in Acadia Pharmaceuticals Inc (ACAD)
This table provides information about the institutional ownership of Acadia Pharmaceuticals Inc (ACAD) during Q3 2023. The information is specifically focused on institutions that hold shares of ACADIA PHARMACEUTICALS INC.
| Report Date | Institution (Fund) | Operation | Option | Shares change | Value Range | Shares Held | Trade History |
|---|---|---|---|---|---|---|---|
|
Nov 14, 2023
Q3 2023
|
Price T Rowe Associates Inc
Baltimore, MD |
SELL
|
- |
-784K- 13.03% |
$16.3M - $26.2M
|
5.23M
$117M
|
|
|
Nov 14, 2023
Q3 2023
|
Steven Cohen
Point72 Asset Management, L.P. | Stamford, Ct
|
SELL
|
- |
-841K- 94.32% |
$17.5M - $28.2M
|
50.6K
$1.13M
|
|
|
Nov 13, 2023
Q3 2023
|
First Trust Advisors LP
Wheaton, IL |
SELL
|
- |
-876K- 34.96% |
$18.2M - $29.3M
|
1.63M
$36.3M
|
|
|
Nov 09, 2023
Q3 2023
|
Deutsche Bank Ag\
Frankfurt Am Main, 2M |
SELL
|
- |
-1.33M- 95.21% |
$27.7M - $44.5M
|
66.9K
$1.49M
|
|
|
Nov 15, 2023
Q3 2023
|
Morgan Stanley
New York, NY |
SELL
|
- |
-1.87M- 50.2% |
$39M - $62.6M
|
1.86M
$41.4M
|
|
|
Nov 13, 2023
Q3 2023
|
Norges Bank
Oslo, Q8 |
SELL
|
- |
-1.98MClosed |
$41.2M - $66.2M
|
0
$0
|